Literature DB >> 29222363

Stability of a pyrimethamine suspension compounded from bulk powder.

Paul O Lewis1, David B Cluck2, Jessica D Huffman3, Amanda P Ogle3, Stacy D Brown4.   

Abstract

PURPOSE: Development of a stability-indicating high-performance liquid chromatography (HPLC) method for pyrimethamine analysis, with subsequent application of that method to assess the 90-day stability of a pyrimethamine suspension compounded from bulk USP-grade pyrimethamine powder, is described.
METHODS: A stability-indicating method of HPLC with ultraviolet detection specific to pyrimethamine was developed according to pharmacopeial recommendations and validated. The method was applied to investigate the stability of a 2-mg/mL pyrimethamine suspension in a vehicle consisting of Ora-Plus and Ora-Sweet (Perrigo) over a period of 90 days. Three replicate test preparations were stored at room temperature or refrigerated at 4.3-5.2 °C, and samples were analyzed in duplicate immediately after preparation and on study days 1, 2, 4, 7, 10, 14, 21, 30, 48, 60, 75, and 90.
RESULTS: The 2-mg/mL suspension of pyrimethamine in Ora-Plus and Ora-Sweet retained 90-110% of the labeled potency to 90 days at both temperature ranges. However, color changes in the samples stored at room temperature observed at day 60 indicated that a beyond-use date less than 90 days from the preparation date should be specified when the suspension is to be stored at room temperature.
CONCLUSION: The study demonstrated that USP-grade pyrimethamine powder can be formulated as a 2-mg/mL suspension in a vehicle of Ora-Plus and Ora-Sweet and is stable when stored at room temperature and when refrigerated, in amber plastic bottles, for 48 and 90 days, respectively.
Copyright © 2017 by the American Society of Health-System Pharmacists, Inc. All rights reserved.

Entities:  

Keywords:  HIV; chromatography; drug stability; high pressure liquid; pyrimethamine; suspensions; toxoplasmosis

Mesh:

Substances:

Year:  2017        PMID: 29222363     DOI: 10.2146/ajhp160551

Source DB:  PubMed          Journal:  Am J Health Syst Pharm        ISSN: 1079-2082            Impact factor:   2.637


  2 in total

1.  Effect of Itraconazole-Ezetimibe-Miltefosine Ternary Therapy in Murine Visceral Leishmaniasis.

Authors:  Valter V Andrade-Neto; Karina M Rebello; Thais M Pereira; Eduardo Caio Torres-Santos
Journal:  Antimicrob Agents Chemother       Date:  2021-02-22       Impact factor: 5.191

2.  Successful Treatment of Cerebral Toxoplasmosis Using Pyrimethamine Oral Solution Compounded From Inexpensive Bulk Powder.

Authors:  Hayley A Hodgson; Taeyong Sim; Hemil Gonzalez; Mariam Aziz; Yoona Rhee; Paul O Lewis; Neel Jhobalia; Beth Shields; Sheila K Wang
Journal:  Open Forum Infect Dis       Date:  2018-04-18       Impact factor: 3.835

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.